Keywords: Ledipasvir; Polyoxyethylene 50 stearate; Spectrofluorimetric determination; Human plasma;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Direct-acting antivirals; Daclatasvir; Ledipasvir; Native fluorescence; Real human plasma; Pharmaceutical formulations;
Keywords: Sofosbuvir; Ledipasvir; Simultaneous determination; Partial least squares; Continues wavelet transform; Derivative spectrophotometry;
Keywords: Binary mixtures; Wavelength-intersection ratio; UV/Vis spectrophotometry; Sofosbuvir; Ledipasvir;
Keywords: Ledipasvir; Sofosbuvir; First derivative spectrophotometric; Conventional dual wavelength method; Isosbestic point method; Absorbance correction method; Absorbance ratio method; Pharmaceutical dosage form; Uniformity of dosage unit; Simultaneous analysis;
Keywords: Direct-acting antivirals; Hepatitis C; Cirrhosis; Sofosbuvir; Ledipasvir; Paritaprevir; Ombitasvir; Simeprevir;
Keywords: Hepatitis C virus; Liver transplant; Direct-acting antivirals; Recurrent hepatitis C virus; Sofosbuvir; Simeprevir; Ledipasvir; Cholestatic hepatitis;
Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice
Keywords: HCV; Glecaprevir; Pibrentasvir; Sofosbuvir; NS5A inhibitor resistance associated variant; P32 deletion; Human hepatocyte chimeric mouse; ASV; asunaprevir; DAAs; Direct-acting antivirals; DCV; daclatasvir; GLE; glecaprevir; HCV; hepatitis C virus; LDV; led
New, simple and sensitive HPTLC method for simultaneous determination of anti-hepatitis C sofosbuvir and ledipasvir in rabbit plasma
Keywords: Sofosbuvir; Ledipasvir; Simultaneous quantitation; High-performance thin-layer chromatography; Dual wavelength detection; Real rabbit plasma;
Spectroflurimetric estimation of the new antiviral agent ledipasvir in presence of sofosbuvir
Keywords: Ledipasvir; Sofosbuvir; Spectroflurimetry; Sofolanork plus;
A facile synthesis of 3D NiFe2O4 nanospheres anchored on a novel ionic liquid modified reduced graphene oxide for electrochemical sensing of ledipasvir: Application to human pharmacokinetic study
Keywords: Ledipasvir; 3D NiFe2O4 nanospheres; Reduced graphene oxide; Morpholinium acid sulphate; Harvoni® tablets; Pharmacokinetic study;
Probing DNA damage induced by common antiviral agents using multiple analytical techniques
Keywords: Antiviral agents; Anticancer agents; Hepatocellular carcinoma; DNA damage; Ledipasvir; Daclatasvir; EvaGreen; Absorption spectroscopy; MALDI-TOF mass spectrometry; Fluorescence spectroscopy;
Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India
Keywords: DAA; Direct Acting Antiviral; DCV; Daclatasvir; EASL; European Association of Study of the Liver (EASL); ETR; End of Treatment Response; HBV; Hepatitis B; HCC; Hepatocellular Carcinoma; HCV; Hepatitis C Virus; HIV; Human Immunedeficiency Virus; ITT; inten
ε-MnO2-modified graphite electrode as a novel electrochemical sensor for the ultrasensitive detection of the newly FDA approved Hepatitis C antiviral drug ledipasvir
Keywords: Ledipasvir; Oxidized ledipasvir; ε- and γ-MnO2 nanoparticles; Graphite electrode; Harvoni® tablets; Rat plasma samples;
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals
Keywords: HCV; RASs; DAA; Virologic Treatment Failure; DAA; direct-acting antiviral; DCV; daclatasvir; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; NS; nonstructural protein; PCR; polymerase chain reaction; PEG IFN; pegylated interf
Consenso Mexicano para el Tratamiento de la Hepatitis C
Keywords: Consenso; Agentes antivirales de acción directa; RegÃmenes libres de interferón; Ribavirina; Consensus; Direct-acting antiviral agents; Interferon-free regimens; Ribavirin; AAD; antivirales de acción directa; AASLD; Asociación Americana para el Estud
The Mexican consensus on the treatment of hepatitis C
Keywords: Consensus; Direct-acting antiviral agents; Interferon-free regimens; Ribavirin; Consenso; Agentes antivirales de acción directa; RegÃmenes libres de interferón; Ribavirina; AASLD; American Association for the Study of Liver Diseases; AFP; alpha-fetopro
Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study
Keywords: LC-MS/MS; Sofosbuvir; Ledipasvir; GS-331007; Human plasma; Pharmacokinetic study; Hepatitis C;
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study
Keywords: Drugs; Generic; Ledipasvir; Sofosbuvir; Hepatitis C;
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
Keywords: Hepatitis C virus; Drug resistance; NS5A; NS5B; DAA; Ledipasvir; Sofosbuvir; Ribavirin;
Effectiveness and Tolerability of Direct Acting Antiviral Therapy for Hepatitis C in a Real World Elderly Cohort
Keywords: DAA; direct acting antiviral; HCV; hepatitis C virus; LDV; ledipasvir; RBV; ribavirin; SMV; simeprevir; SOF; sofosbuvir; SVR12; sustained virologic response;
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome
Keywords: NS5A RAS; HCV genotype 1; Ledipasvir; Sofosbuvir; Sustained virologic response; Genotype; Treatment outcome;
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective
Keywords: cost-effectiveness; daclatasvir; Egypt; hepatitis C virus; ledipasvir; sofosbuvir;
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Keywords: Hepatitis C, Chronic; Genotype 1; Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Ledipasvir; Sofosbuvir; Real-world; Antiviral agents; Sustained virologic response; Randomized controlled trials;
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis
Keywords: Ledipasvir; Sofosbuvir; Ribavirin; Hepatitis C virus infection; Meta-analysis;
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Keywords: Routine Clinical Practice; Direct-Acting Antiviral Agents; Cirrhosis; Genotype 4; DAA; direct-acting antiviral agent; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; OMV; ombitasvir; PTV; paritaprevir; r; ritonavir; RBV; riba
Study on the forced degradation behaviour of ledipasvir: Identification of major degradation products using LC-QTOF-MS/MS and NMR
Keywords: Ledipasvir; Forced degradation studies; HPLC; LC-MS; NMR;
Finally, safe and effective treatment options for hepatitis C in hemodialysis patients
Keywords: HCV; hepatitis C virus; ESRD; end-stage renal disease; HD; hemodialysis; DAA; direct acting antivirals, SOF, sofosbuvir; SIM; simeprevir; LED; ledipasvir; DCV; daclatasvir; RBV; ribavirn; IFN; interferon; SVR; sustained virologic response; pk; pharmacokin
Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS and its application to a pharmacokinetic study
Keywords: Ledipasvir; Sofosbuvir; GS-331007; UPLC–MS/MS; Plasma; Pharmacokinetics
Les nouveaux médicaments de l’infectiologie
Keywords: dasabuvir; lédipasvir; ombitasvir; paritaprévir; ritonavir; sofosbuvir; virus varicelle-zonadasabuvir; ledipasvir; ombitasvir; paritaprevir; ritonavir; sofosbuvir; varicella-zoster virus
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Keywords: HCV; hepatitis C virus; DAA; direct-acting antiviral; MELD; model for end-stage liver disease; SVR; sustained virological response; EAP; expanded access programme; HCVRUK; hepatitis C Research UK; SOF; sofosbuvir; LDV; ledipasvir; DCV; daclatasvir; RBV; r
Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: Application to fasting and fed bioequivalence studies
Keywords: Sofosbuvir; Ledipasvir; UPLC-MS/MS; Plasma; Validation; Bioequivalence;
Research ArticlePharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
Keywords: HCV; hepatitis C Virus; ESRD; end-stage renal disease; DAAs; direct-acting anti-HCV agents; SOF; sofosbuvir; LDV; ledipasvir; SOF-007TP; sofosbuvir uridine-triphosphate; SOF-007; predominant sofosbuvir inactive metabolite GS-331007; QD; once daily; TIW; t
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient
Keywords: ALT; alanine aminotransferase; AST; aspartate aminotransferase; cART; combination antiretroviral therapy; DAA; direct-acting antiviral; DDI; drug-drug interaction; EOTR; end-of-treatment response; GT; genotype; HCV; hepatitis C virus; HIV-1; human immun
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response
Keywords: DAA; NS5A Inhibitor; NS5B Inhibitor; Antiviral; AE; adverse events; CI; confidence interval; HCV; hepatitis C virus; LDV; ledipasvir; OR; odds ratio; PPI; proton pump inhibitor; RBV; ribavirin; SOF; sofosbuvir; SVR; sustained virologic response; SVR12; su
Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015
Keywords: SOF; Sofosbuvir; DCV; Daclatasvir; RBV; Ribavirin; CP; Child-Pugh; SVR; Sustained virologial response; HVPG; Hepatic venous pressure gradient; G; Genotype; LDV; Ledipasvir; GZR; grazoprevir; EBR; Elbasvir; SMV; Simeprevir; CKD; Chronic kidney disease; RAV
Hepatitis C Virus
Keywords: Direct-acting antivirals; Sofosbuvir; Ledipasvir; Paritaprevir; Ombitasvir; Egypt; Access to treatment; Screening;
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
Keywords: Antiviral Agent; Replication; Therapy; RNA-Dependent RNA Polymerase; BOC; boceprevir; CI; confidence interval; DAA; direct-acting antiviral; DCV; daclatasvir; EC50; 50% effective concentration; FFU; focus-forming unit; GLuc; Gaussia princeps luciferase; H